Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJID (3) Autor Bonora,Stefano (1) Calcagno,Andrea (1) Campos,Silvia V (1) Castelo,A. (1) Dalben,Mirian (1) Diaz,RS. (1) Freitas,Angela C (1) Hernandez,Adrian V (1) Lanzafame,Massimiliano (1) Lattuada,Emanuela (1) Lunardi,L. (1) Palacios,R. (1) Senise,J.F. (1) Song,Alice TW (1) Tanno,Z.N. (1) Vaz,M.J.R. (1) Vento,Sandro (1) Vidal,Jose E (1) Waghabi,G.R. (1) Mais... Palavra-chave Highly active (3) Antiretroviral therapy (2) Brazil (2) Acquired immunodeficiency syndrome (1) Disease transmission (1) HIV infections (1) HIV protease inhibitors (1) HIV-1 (1) Pharmacokinetics antiretroviral therapy (1) Vertical transmission (1) Viral load (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Info:eu-repo/semantics/report (1) Ano 2011 (2) 2006 (1) País Brazil (3) Idioma Inglês (3)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 3 Primeira ... 1 ... Última HIV-1 viremia during the first 28 weeks of pregnancy is not associated with mother-to-child transmission BJID Senise,J.F.; Palacios,R.; Tanno,Z.N.; Lunardi,L.; Waghabi,G.R.; Vaz,M.J.R.; Diaz,RS.; Castelo,A.. It is currently recommended that antiretroviral prophylaxis to prevent mother-to-child transmission (MTCT) of HIV be initiated at 14 weeks of gestation. However, the relevance of early-gestation HIV viral load level for intrauterine MTCT is unknown. The objective of this study was to determine the relationship between prenatal maternal viral load and intrauterine MTCT. Records of HIV-infected pregnant women in two centers in Brazil, from 1999 to 2004 were analyzed. Three pregnancy periods were considered: earlier than 14 weeks, 14 to 27 6/7 weeks, and 28 weeks of gestation or more. Peripartum HIV exposure was also computed. Maximum viral load in each period was the measure of HIV exposure. Four hundred fifty-seven HIV-infected pregnant women were... Tipo: Info:eu-repo/semantics/article Palavras-chave: HIV-1; Disease transmission; Vertical transmission; Antiretroviral therapy; Highly active; Brazil; Viral load. Ano: 2006 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000400009 A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients BJID Lanzafame,Massimiliano; Bonora,Stefano; Lattuada,Emanuela; Calcagno,Andrea; Vento,Sandro. Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication Tipo: Info:eu-repo/semantics/report Palavras-chave: HIV infections; Pharmacokinetics antiretroviral therapy; Highly active. Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000500017 Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil BJID Vidal,Jose E; Freitas,Angela C; Song,Alice TW; Campos,Silvia V; Dalben,Mirian; Hernandez,Adrian V. Information about resistance profile of darunavir (DRV) is scarce in Brazil. Our objectives were to estimate the prevalence of DRV resistance mutations in patients failing protease inhibitors (PI) and to identify factors associated with having more DRV resistance mutations. All HIV-infected patients failing PI-based regimens with genotyping performed between 2007 and 2008 in a referral teaching center in São Paulo, Brazil, were included. DRV-specific resistance mutations listed by December 2008 IAS-USA panel update were considered. Two Poisson regression models were constructed to assess factors related to the presence of more DRV resistance mutations. A total of 171 HIV-infected patients with available genotyping were included. The number of patients with... Tipo: Info:eu-repo/semantics/article Palavras-chave: Antiretroviral therapy; Highly active; HIV protease inhibitors; Acquired immunodeficiency syndrome; Brazil. Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000300011 Registros recuperados: 3 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco